All of a sudden, dementia treatment becomes 'exciting'

And for Intellia Therapeutics, CRISPR drug's safety concern is an existential threat, Adam Feuerstein writes

October 27, 2025 Check out STAT+

Sponsored By

Ruby Wallau for STAT STAT+ | Intellia pauses two late-stage CRISPR gene-editing trials after emergence of safety concern The company has previously encountered few serious safety concerns, despite dosing hundreds of patients across its clinical trials. By Jason Mast STAT+ | For Intellia Therapeutics, CRISPR drug's safety concern is an existential threat The company will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, potentially fatal, liver toxicity. By Adam Feuerstein STAT+ | Chinese biotech industry shows no signs of slowing as threat of U.S. restrictions loom  Drugmakers — once seen as a source of "me-too" drugs — are advancing at a rapid clip, churning out novel medications and threatening to overtake the U.S. By Brian Yang Molly Ferguson for STAT STAT+ | Opinion: All of a sudden, dementia treatment is becoming very exciting Biomarker-based therapeutics and better diagnoses are changing dementia care in deeply meaningful ways for patients, families, and physicians. By Jason Karlawish When SNAP benefits run out, 'people can die,' say health experts Failure to send out SNAP benefits in November will particularly hurt people with diabetes, hypertension, and chronic kidney disease. By Sarah Todd STAT+ | CAR-T therapies from Cabaletta, Bristol Myers Squibb induce remissions in patients with autoimmune disorders Small trials add to evidence personalized cell therapies may prove to be curative for patients with serious autoimmune disorders. By Adam Feuerstein Spencer Platt/Getty Images STAT+ | For heart health, physical activity favors women Study finds exercising 150 minutes a week lowered the risk of coronary heart disease by 22% in women, 17% in men. The reason for the gap was not identified. By Elizabeth Cooney

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser